文献速递认知障碍与痴呆

鼻内胰岛素治疗轻度认知障碍与阿尔茨海默病痴呆的安全性和有效性

Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2020-01-01

这项随机双盲2/3期多中心试验纳入289例轻度认知障碍或阿尔茨海默病痴呆患者,每日给予40 IU鼻内胰岛素或安慰剂治疗12个月。在主要意向治疗人群(使用第二装置给药的240例)中,鼻内胰岛素在ADAS-cog-12评分变化及临床或脑脊液结局上均未显示优于安慰剂,且未观察到与治疗相关的临床重要不良事件。

要点

  • 鼻内胰岛素40 IU每日治疗12个月未改善认知或功能结局。
  • 主要意向治疗人群中ADAS-cog-12评分变化组间无差异。
  • 未观察到与鼻内胰岛素治疗相关的临床重要不良事件。

核心结论

  • 在主要意向治疗队列中,鼻内胰岛素治疗12个月未观察到认知或功能获益。

研究设计与样本

  • 随机(1:1)双盲2/3期多中心临床试验,2014至2018年在27个中心开展。
  • 筛查432例成人,排除144例,最终随机289例55至85岁遗忘型轻度认知障碍或阿尔茨海默病痴呆患者。
  • 干预为每日40 IU胰岛素或安慰剂,双盲期12个月,随后6个月开放标签扩展期。
  • 前49例所用第一装置可靠性不一致,其余240例使用第二装置并作为主要意向治疗人群。

主要发现

  • 主要分析中其他临床结局及脑脊液结局均未见组间差异。
  • 未观察到与治疗相关的临床重要不良事件。

关键数值与推荐

  • 纳入标准包括年龄55至85岁、基于NIA-AA标准诊断遗忘型轻度认知障碍或阿尔茨海默病、MMSE评分≥20、临床痴呆评定量表0.5或1.0。
  • 主要结局为ADAS-cog-12平均评分变化,每3个月评估一次;次要临床结局每6个月评估。

临床怎么用

  • 现有证据不支持将鼻内胰岛素40 IU每日方案用于轻度认知障碍或阿尔茨海默病痴呆的常规治疗。

局限性

  • 前49例所用第一装置可靠性不一致,主要分析仅基于使用第二装置的240例参与者。
  • 开放标签扩展期可能影响长期结局的解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Insulin modulates aspects of brain function relevant to Alzheimer disease and can be delivered to the brain using intranasal devices. To date, the use of intranasal insulin to treat persons with mild cognitive impairment and Alzheimer's disease dementia remains to be examined in a multi-site trial. OBJECTIVE: To examine the feasibility, safety, and efficacy of intranasal insulin for the treatment of persons with mild cognitive impairment and Alzheimer disease dementia in a phase 2/3 multisite clinical trial. DESIGN, SETTING, AND PARTICIPANTS: A randomized (1:1) double-blind clinical trial was conducted between 2014 and 2018. Participants received 40 IU of insulin or placebo for 12 months during the blinded phase, which was followed by a 6-month open-label extension phase. The clinical trial was conducted at 27 sites of the Alzheimer's Therapeutic Research Institute. A total of 432 adults were screened, and 144 adults were excluded. Inclusion criteria included adults aged 55 to 85 years with a diagnosis of amnestic mild cognitive impairment or Alzheimer disease (based on National Institute on Aging-Alzheimer Association criteria), a score of 20 or higher on the Mini-Mental State Examination, a clinical dementia rating of 0.5 or 1.0, and a delayed logical memory score within a specified range. A total of 289 participants were randomized. Among the first 49 participants, the first device (device 1) used to administer intranasal insulin treatment had inconsistent reliability. A new device (device 2) was used for the remaining 240 participants, who were designated the primary intention-to-treat population. Data were analyzed from August 2018 to March 2019. INTERVENTIONS: Participants received 40 IU of insulin (Humulin-RU-100; Lilly) or placebo (diluent) daily for 12 months (blinded phase) followed by a 6-month open-label extension phase. Insulin was administered with 2 intranasal delivery devices. MAIN OUTCOMES AND MEASURES: The primary outcome (mean score change on the Alzheimer Disease Assessment Scale-cognitive subscale 12) was evaluated at 3-month intervals. Secondary clinical outcomes were assessed at 6-month intervals. Cerebrospinal fluid collection and magnetic resonance imaging scans occurred at baseline and 12 months. RESULTS: A total of 289 participants (155 men [54.6%]; mean [SD] age, 70.9 [7.1] years) were randomized. Of those, 260 participants completed the blinded phase, and 240 participants completed the open-label extension phase. For the first 49 participants, the first device used to administer treatment had inconsistent reliability. A second device was used for the remaining 240 participants (123 men [51.3%]; mean [SD] age, 70.8 [7.1] years), who were designated the primary intention-to-treat population. No differences were observed between treatment arms for the primary outcome (mean score change on ADAS-cog-12 from baseline to month 12) in the device 2 ITT cohort (0.0258 points; 95% CI, -1.771 to 1.822 points; P = .98) or for the other clinical or cerebrospinal fluid outcomes in the primary (second device) intention-to-treat analysis. No clinically important adverse events were associated with treatment. CONCLUSIONS AND RELEVANCE: In this study, no cognitive or functional benefits were observed with intranasal insulin treatment over a 12-month period among the primary intention-to-treat cohort. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01767909.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Craft S, Raman R, Chow TW, et al. Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial. JAMA Neurol. 2020. PMID: 32568367. doi:10.1001/jamaneurol.2020.1840

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。